Notably, it was demonstrated that miR-22 was subject to epigenetic regulation by the methyl-CpG-binding protein 2 (MeCP2), which resulted in the reversion of miR-22 effects, allowing us to propose the MeCP2-miR-22-MTHFD2-MTHFR axis as a potential therapeutic target for GC treatment [70]. This evidence concerns the gene MTHFR and gastric cancer.